2 active not recruiting, 2 recruiting, 1 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Unresectable Gastric Carcinoma: new trials by email Literature Review of Unresectable Gastric Carcinoma trials Research Report on Unresectable Gastric Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-27 |
| First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) Disitamab Vedotin, Sintilimab, S-1 - HER2-positive Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 110 | 2024-10-17 | 2026-09-15 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2018-02-06 | 2026-02-03 |
Stomach Neoplasms (5) · Esophageal Neoplasms (2) · Neoplasm Metastasis (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Salivary Gland Neoplasms (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Stomach Diseases (5) · Head and Neck Neoplasms (3) · Esophageal Diseases (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Breast Diseases (1) · Colonic Diseases (1) · Female Urogenital Diseases (1)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Ramucirumab (2) · Specimen Handling (2) · trastuzumab deruxtecan (2) · Capecitabine (1) · Cisplatin (1) · Fluorouracil (1) · Oxaliplatin (1) · Paclitaxel (1) · S 1 (combination) (1) · Trastuzumab (1) · balstilimab (1) · ceralasertib (1) · disitamab vedotin (1)
National Cancer Institute (NCI) (3) · Memorial Sloan Kettering Cancer Center (1) · Qilu Hospital of Shandong University (1)
United States (4) · China (1)
Funda Meric-Bernstam (1) · Kanwal P Raghav (1) · Lian Liu, MD (1) · Michael Cecchini (1) · Yelena Janjigian, MD (1)
UM1CA186688 (2), UM1CA186689 (1)